Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaoundé-Cameroon

PLoS One. 2017 Nov 7;12(11):e0187566. doi: 10.1371/journal.pone.0187566. eCollection 2017.

Abstract

Introduction: Limited studies have reported the outcomes of lifelong antiretroviral therapy (ART) amongst adolescents living with HIV (ALWHIV) in resource-limited settings (RLS), thus classifying this population as underserved. We therefore aimed to ascertain the immunological and virological responses, and associated factors amongst Cameroonian ALWHIV.

Method: A cross-sectional and observational study was conducted from January through May 2016 at the National Social Insurance Fund Health Centre in Yaoundé-Cameroon. Immunological and virological responses were evaluated using CD4 cell count and viral load respectively, with viral suppression (VS) defined as <50 copies/ml. Adherence was evaluated using self-reported missing doses during the past 14 days. Data were analyzed using R v.3.3.0, with p<0.05 considered statistically significant.

Results: Of the 145 ALWHIV on ART enrolled in the study, 52% were female, median age [interquartile (IQR)] was 13 [11-16] years, median [IQR] time-on-ART was 7 [5-10] years, 48% were orphans, 92% were on first-line ART and 36% were adherent to ART. Following ART response, 79% (114/145) had CD4 ≥500/mm3, 71.0% (103/145) were on VS of whom 52.4% (76/145) had a sustained VS. Duration of ART was associated with immune restoration (Odd Ratio 3.73 [1.26-12.21]) but not with virological response. Risks of poor adherence were greater in orphans of both parents (p = 0.078).

Conclusion: In this urban setting of Cameroon, ALWHIV receiving ART show favorable immunological and virological response in a medium run. For long-term ART success, implementing a close monitoring of adherence and risks of viral rebound would be highly relevant, especially for orphans of both parents.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Anti-HIV Agents / therapeutic use
  • Cameroon
  • Cross-Sectional Studies
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Infections / transmission
  • HIV Infections / virology*
  • HIV-1
  • Humans
  • Infectious Disease Transmission, Vertical*
  • Male
  • Viral Load

Substances

  • Anti-HIV Agents

Grants and funding

The author(s) received no specific funding for this work.